Payment overview · 2025
General Payments
$342.15
28 reported records · 6 companies
Healthcare provider profile · identity verified
Sri Devi Kolli, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FENTON, MO · NPI 1558308361
Verified facts
What the public records show
CMS Open Payments records show Sri Devi Kolli, M.D. received $342.15 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.85 | 49.9% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.22 | 15.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.94 | 14.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.54 | 11.8% | 2 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $13.99 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.61 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.15 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $170.85 | 18 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 118 |
| Lisinopril | Lisinopril | 353 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 104 |
| Gabapentin | Gabapentin | 293 | 76 |
| Simvastatin | Simvastatin | 252 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 73 |
| Losartan Potassium | Losartan Potassium | 226 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 192 | 58 |
| Trazodone Hcl | Trazodone Hcl | 175 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 24 |
| Furosemide | Furosemide | 146 | 49 |
| Candesartan Cilexetil | Candesartan Cilexetil | 140 | 35 |
| Allopurinol | Allopurinol | 132 | 36 |
| Omeprazole | Omeprazole | 121 | 36 |
| Metformin Hcl | Metformin Hcl | 120 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 36 |
| Montelukast Sodium | Montelukast Sodium | 117 | 34 |
| Alprazolam | Alprazolam | 112 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 111 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 41 |
| Meloxicam | Meloxicam | 104 | 34 |
| Sertraline Hcl | Sertraline Hcl | 81 | 27 |
| Alendronate Sodium | Alendronate Sodium | 80 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 22 |
| Ezetimibe | Ezetimibe | 70 | 19 |
| Trulicity | Dulaglutide | 69 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 19 |
| Jardiance | Empagliflozin | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 66 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 13 |
| Carvedilol | Carvedilol | 64 | 20 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Potassium Chloride | Potassium Chloride | 62 | 20 |
| Azithromycin | Azithromycin | 61 | 50 |
| Eliquis | Apixaban | 60 | 20 |
| Famotidine | Famotidine | 60 | 22 |
| Bupropion Xl | Bupropion Hcl | 59 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 19 |
| Baclofen | Baclofen | 57 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Methylprednisolone | Methylprednisolone | 52 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 16 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Celecoxib | Celecoxib | 45 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Donepezil Hcl | Donepezil Hcl | 42 | 12 |
| Atenolol | Atenolol | 41 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Lorazepam | Lorazepam | 40 | 14 |
| Prednisone | Prednisone | 40 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 15 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Metformin Hcl Er | Metformin Hcl | 37 | 13 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 37 | 13 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Ozempic | Semaglutide | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Torsemide | Torsemide | 31 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.15 · 28 records | ABBVIE INC. | AIRSUPRA, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error